CLINICAL PERSPECTIVES OF PLATELET TRANSFUSIONS - DEFINING THE OPTIMAL DOSE

被引:22
作者
STRAUSS, RG [1 ]
机构
[1] UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242
关键词
THROMBOCYTOPENIA; GRAFT VS HOST DISEASE; LEUKOFILTRATION; PLATELET; PLATELET TRANSFUSIONS;
D O I
10.1002/jca.2920100305
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To halt bleeding in patients with severe thrombocytopenia due to bone marrow failure, it is desirable to achieve a post-transfusion blood platelet count of 40 x 10(9)/L by platelet transfusions. Based on calculations of corrected count increments, each 1 x 10(11) platelets transfused will increase the blood platelet count approximately 10 x 10(9)/L per each square meter of patient body surface area. Thus, the post-transfusion blood platelet count will be approximately 20 x 10(9)/L following transfusion of 3 x 10(11) platelets to a 5 foot, 8 inch patient weighing 170 pounds (2.0 m(2)), who is bleeding because of a pre-transfusion platelet count of 5 x 10(9)/L. The post-transfusion platelet count likely will be even lower in sick patients (sepsis, amphotericin B plus antibiotic therapy, splenomegaly, graft-vs.-host disease, etc.) or if platelets are lost from the unit by leukofiltration before transfusion. Although a dose of 3 x 10(11) platelets is acceptable, in a regulatory sense for product quality, it is inadequate to control bleeding in most thrombocytopenic adult patients. Adjusting dose for body size, bleeding patients with pre-transfusion blood platelet of <10 x 10(9)/L and weighing >120 pounds should receive approximately 6 x 10(11) platelets, those weighing 30 to 120 pounds should receive 3 x 10(11) platelets, and infants weighing <30 pounds (15 kg) should receive 5-10 ml/kg of platelet concentrate. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:124 / 127
页数:4
相关论文
共 6 条
[1]   BLOOD CENTER PERSPECTIVE - DEFINING THE IDEAL PLATELET CONCENTRATE [J].
AXELROD, FB ;
OOLEY, PW .
JOURNAL OF CLINICAL APHERESIS, 1995, 10 (03) :128-130
[2]   USE OF SPLIT PLATELETPHERESIS PRODUCTS FOR ALLOIMMUNIZED PATIENTS [J].
GHARPURE, VS ;
NORRIS, D ;
LEE, EJ ;
SCHIFFER, CA .
VOX SANGUINIS, 1994, 67 (03) :272-274
[3]  
HEYMAN MR, 1990, SEMIN ONCOL, V17, P198
[4]  
SHANWELL A, 1992, EUR J HAEMATOL, V49, P77
[5]  
STRAUSS RG, 1986, PLASMA THER TRANSFUS, V7, P279
[6]  
TORNEBOHM E, 1993, EUR J HAEMATOL, V50, P160